Companies · Biotechnology

Rebiotix Inc.

Roseville · Biotechnology

Diligence memoA one-page analyst read on Rebiotix Inc. — recommendation, valuation, rhythm, risks.
$29.3M
Total raised · real
3
Rounds
0.5×
Latest step-up
Top 27%
Sector rank · raised
Series B
Latest stage · inferred · Thu Aug 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Rebiotix Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.43× the median modeled value of Series B Biotechnology companies in 2016–2018 (101 peers) — value vs value, same stage and era.
Dormant
  • Last raise 8.9 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Rebiotix Inc. is one of 4293 Biotechnology companies tracked from Roseville. By capital raised it ranks in the upper tier (ahead of 74% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(c)
Reg D exemption
29
Investors (latest)
2017-08-24
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeed · 2011-11-01 Raised $2.8M (real) Modeled valuation $123M (est)$2.8M$123MSeed2011Series B · 2014-06-25 Raised $18M (real) Modeled valuation $714M (est)$18M$714MSeries B2014Series B · 2017-08-24 Raised $8.5M (real) Modeled valuation $338M (est)$8.5M$338MSeries B2017+$18M+$8.5MCumulative $29M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.8M · 2011
Series B$18.0M · 2014no Series A on file
Series B extension$8.5M · 2017

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$338.0M
Base estimate est.
$17.0M
Conservative case
$1.3B
Upside case
$47.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $123.4M · 2011-11-012011Series B · modeled $714.4M · 2014-06-25Series B · modeled $338.0M · 2017-08-242017
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
6.0 yr
Elapsed time used
8.8 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
35 mo
Avg between rounds
$5.0M/yr
Capital velocity
14.7 yr
On record since
2011
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 4.1× above median
This company$29.3M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.5× of median
This company$8.5M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 5.3× above median
This company$338.0M
Sector median$64.2M

Raised more than 74% of sector peers (real $). Modeled value above 78% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #77 of 101.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Liquid BioScience, Inc. · Series B Raised $40.0M · modeled $1.6B (est)Amphivena Therapeutics, Inc. · Series B Raised $65.2M · modeled $1.5B (est)Tracon Pharmaceuticals, Inc. · Series B Raised $57.7M · modeled $1.5B (est)Tetra Discovery Partners, Inc. · Series B Raised $40.5M · modeled $1.4B (est)ECM Therapeutics, Inc. · Series B Raised $35.2M · modeled $1.4B (est)Recombinetics, Inc · Series B Raised $54.7M · modeled $1.3B (est)Mersana Therapeutics Inc · Series B Raised $93.7M · modeled $1.3B (est)Atox Bio Inc. · Series B Raised $35.1M · modeled $1.3B (est)Valeritas Holdings Inc. · Series B Raised $58.2M · modeled $1.3B (est)Obsidian Therapeutics, Inc. · Series B Raised $32.4M · modeled $1.3B (est)Cellular Biomedicine Group, Inc. · Series B Raised $40.5M · modeled $1.2B (est)Altor Bioscience Corp · Series B Raised $80.1M · modeled $1.2B (est)Rebiotix Inc. (this company) Raised $29.3M · modeled $338.0M (est)Rebiotix Inc.
CompanyStageRaised · realValue · estvs peer med.
Liquid BioScience, Inc.Series B$40.0M$1.6B2.00×
Amphivena Therapeutics, Inc.Series B$65.2M$1.5B1.93×
Tracon Pharmaceuticals, Inc.Series B$57.7M$1.5B1.93×
Tetra Discovery Partners, Inc.Series B$40.5M$1.4B1.79×
ECM Therapeutics, Inc.Series B$35.2M$1.4B1.76×
Recombinetics, IncSeries B$54.7M$1.3B1.68×
Mersana Therapeutics IncSeries B$93.7M$1.3B1.65×
Atox Bio Inc.Series B$35.1M$1.3B1.65×
Valeritas Holdings Inc.Series B$58.2M$1.3B1.65×
Obsidian Therapeutics, Inc.Series B$32.4M$1.3B1.62×
Cellular Biomedicine Group, Inc.Series B$40.5M$1.2B1.53×
Altor Bioscience CorpSeries B$80.1M$1.2B1.52×
Rebiotix Inc. this companySeries B$29.3M$338.0M0.43×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.8M2011-11-01$13.9M$123.4M85%
Series B$18.0M2014-06-25$100.0M$714.4M85%
Series B$8.5M2017-08-24$47.3M$338.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.8M2011-11-01
    • First recorded raise — entered as Seed.
    • 28 investors on this round.
  2. Series B$18.0M2014-06-25
    • Raised again after 32 mo — slower than the ~14 mo sector norm.
    • Round 6.5× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
    • 6 investors on this round.
  3. Series B$8.5M2017-08-24
    • Raised again after 38 mo — slower than the ~14 mo sector norm.
    • Round 2.1× smaller than the prior — bridge or down round.
    • Switched to Rule 506(c) (was Rule 506(b)).
    • 29 investors on this round.
Intelligence
2020 ~Q3
Modeled next raise · ~35mo cadence
$8.5M
Modeled next size est.range $8.5M$13.6M
0.5×
Last step-up
$5.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Michael Berman6 other2011-11
Erwin Kelen4 other2011-11
William McGuire3 other2014-06
Greg Fluet2017-08
Lee Jones2011-11
Nancy Timm2014-06
Registry & provenance

Rebiotix Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1532997
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Reprise Biomedical, Inc.BiotechnologySeries B$47.1M$29.7Mnetwork1 shared operator · same sector · same stage
Basking Biosciences, Inc.BiotechnologySeries B$29.4M$261.3Msame sector · same stage
Spyryx Biosciences, Inc.BiotechnologySeries B$29.1M$235.4Msame sector · same stage
Cadence Neuroscience, Inc.BiotechnologySeries B$29.0M$332.6Msame sector · same stage
Achieve Life Sciences, Inc.BiotechnologySeries B$28.9M$270.0Msame sector · same stage
Neuraptive Therapeutics, Inc.BiotechnologySeries B$29.8M$295.3Msame sector · same stage
Gemelli Biotech Corp.BiotechnologySeries B$28.5M$454.3Msame sector · same stage
Unnatural Products Inc.BiotechnologySeries B$30.1M$269.8Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
BioRegenx Inc.BiotechnologyPre-Seed$2.1M93%
Remunix, Inc.BiotechnologySeries B$129.4M92%
Reata Pharmaceuticals IncBiotechnologySeries D+$2.1B92%
Remedium Bio Inc.BiotechnologySeries A$83.8M91%
Rejuvitas, Inc.BiotechnologySeries A$63.6M90%
BioPlx, Inc.BiotechnologySeed$47.8M90%
Biorez, Inc.BiotechnologySeries A$89.1M90%
BioNADrx Holdings, Inc.BiotechnologyPre-Seed$748K90%
Frequently asked
How much funding has Rebiotix Inc. raised?
Rebiotix Inc. has raised approximately $29.3M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Rebiotix Inc.'s estimated valuation?
Provath's modeled valuation for Rebiotix Inc. is approximately $338.0M (modeled range $17.0M–$1.3B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Rebiotix Inc. at?
Rebiotix Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Thu Aug 24.
What does Rebiotix Inc. do and where is it based?
Rebiotix Inc. operates in the Biotechnology sector, based in Roseville.
Explore related

See where Rebiotix Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Rebiotix Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.